¹ÙÀÌ·¯½º°£¿°ÀÇ ÃÖ½ÅÁö°ß ¹× °£¼¶À¯È °Ë»çÀÇ ÀÌÇØ : 2023-06-02
±³À°ÀÏÀÚ : 2023-06-02
±³À°Àå¼Ò : º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦
±³À°ÁÖÁ¦ : ¹ÙÀÌ·¯½º°£¿°ÀÇ ÃÖ½ÅÁö°ß ¹× °£¼¶À¯È °Ë»çÀÇ ÀÌÇØ
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ÀüºÏÁöȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : Àü¶óºÏµµ
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 18:30~19:00 Chronic B Viral Hepatitis : Need for Treatment of Gray zone? ÀÌâÈÆ(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 19:00~19:30 Chronic C Viral Hepatitis : Use of Pan-genotypic agents ±èÀÎÈñ(ÀüºÏÀÇ´ë)
Åä·Ð 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 19:30~19:40 Discussion ( )
±³À°½Ã°£ 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 19:40~20:20 Clinical Usefulness of M2BPGi in the Evaluation of Liver Fibrosis Àü´ë¿ø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 20:20~20:50 Benefits and Limitation of Serological Tests Á¤±Ý¸ð(¿¹¼öº´¿ø)
±³À°½Ã°£ 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 20:50~21:20 The Role of Radiological Surrogates Á¶ÈƱæ(¿ø±¤ÀÇ´ë)
Åä·Ð 06¿ù 02ÀÏ º£½ºÆ®¿þ½ºÅÏÇ÷¯½ºÀüÁÖÈ£ÅÚ 2Ãþ º£½ºÆ®È¦ 21:20~21:30 Discussion ( )